deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT04578834

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

Sponsor: Novartis Pharmaceuticals

Conditions IgA Nephropathy
Interventions LNP023 Placebo
Updated 36 times since 2020 Last updated: Dec 22, 2025 Started: Jan 25, 2021 Primary completion: Sep 19, 2025 Completion: Sep 19, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates IgA Nephropathy and is currently completed. Novartis Pharmaceuticals leads this study, which shows 36 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshot~Apr 2021 – ~Jun 2021 · 2 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Dec 2021 · 30 days · monthly snapshot~Dec 2021 – ~Jan 2022 · 31 days · monthly snapshot~Jan 2022 – ~Mar 2022 · 59 days · monthly snapshot~Mar 2022 – ~May 2022 · 2 months · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Feb 2024 · 31 days · monthly snapshot~Feb 2024 – ~Jun 2024 · 4 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshot~Apr 2025 – ~Aug 2025 · 4 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – ~Jan 2026 · 2 months · monthly snapshot~Jan 2026 – present · 7 months · monthly snapshot

Change History

36 versions recorded

  1. Jan 2026 — Present [monthly]

    Completed PHASE3

  2. Nov 2025 — Jan 2026 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  3. Sep 2025 — Nov 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  5. Apr 2025 — Aug 2025 [monthly]

    Active Not Recruiting PHASE3

▶ Show 31 earlier versions

  1. Jan 2025 — Apr 2025 [monthly]

    Active Not Recruiting PHASE3

  2. Oct 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2024 — Aug 2024 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

  7. Feb 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE3

  8. Jan 2024 — Feb 2024 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE3

  10. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE3

  11. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  12. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  13. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  14. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

  15. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  16. Jan 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  17. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  18. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  19. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE3

  20. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE3

  21. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE3

  22. Mar 2022 — May 2022 [monthly]

    Recruiting PHASE3

  23. Jan 2022 — Mar 2022 [monthly]

    Recruiting PHASE3

  24. Dec 2021 — Jan 2022 [monthly]

    Recruiting PHASE3

  25. Nov 2021 — Dec 2021 [monthly]

    Recruiting PHASE3

  26. Sep 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  27. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  28. Apr 2021 — Jun 2021 [monthly]

    Recruiting PHASE3

  29. Mar 2021 — Apr 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  30. Jan 2021 — Mar 2021 [monthly]

    Not Yet Recruiting PHASE3

  31. Nov 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis Pharmaceuticals
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aalborg, Denmark , Adelaide, Australia , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Antalya, Turkey (Türkiye) , Arhus N, Denmark , Ashkelon, Israel , Aurora, United States , Baltimore, United States and 136 more locations